Under construction – not a live service

Skip to content

Frontlight Research

Trial site

Charite Research Organisation GmbH

Berlin, 12203, GermanyNot linked to an institution yet

22running trials
26closed trials

The trials here

What the 50 trials at this site are about, from their registry records.

Conditions: Obesity8 trials
Ulcerative colitis7 trials
Lupus (SLE)5 trials
Lung cancer4 trials
Rheumatoid arthritis4 trials
Atopic dermatitis (eczema)3 trials
Colorectal cancer3 trials
Gastric and oesophageal cancer3 trials
Melanoma3 trials
Metastatic breast cancer3 trials
Triple-negative breast cancer3 trials
Asthma2 trials
and 24 more
Phase: Phase 136 trials
Phase 25 trials
Phase 35 trials
Phase 1/24 trials
Status: Completed26 trials
Recruiting12 trials
Active, not recruiting7 trials
Not yet recruiting3 trials
Suspended2 trials
Lead sponsor: Novo Nordisk A/S7 trials
Boehringer Ingelheim3 trials
Seagen Inc.3 trials
Bristol-Myers Squibb2 trials
Granite Bio AG2 trials
and 28 more

Running trials

Not yet recruiting
An Open-label, DDI Study to Investigate the Effects of Duvakitug on the PK of Selected Cytochrome P450 Substrates
NCT07923383· Phase 1· Sanofi· Source
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704· Phase 1/2· Bristol-Myers Squibb· Source
Recruiting
A Phase 1b Basket Study Evaluating B Cell Depletion in Blood and Tissue by Etentamig or ABBV-519 in Subjects with Moderate to Severe Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), or Sjögren's Disease (SjD)
2026-526282-25-00· Phase 1· AbbVie Deutschland GmbH & Co. KG· Source
Recruiting
A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or Obesity
NCT07815067· Phase 1· Novo Nordisk A/S· Source
Not yet recruiting
A Phase I single-blind, randomised, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of single and multiple rising doses of SIM0709 in healthy participants
2026-527412-16-00· Phase 1· Simcere Pharmaceutical Co. Ltd.· Source
Recruiting
A research study looking into how a single dose of the medicine NNC0537-1482 moves through the body of participants with normal or reduced kidney function
2026-525271-57-00· Phase 1· Novo Nordisk A/S· Source
Recruiting
A Study to Evaluate the Safety and Activity of an Inhaled Investigational Drug (RO7616605) in Healthy Volunteers and Participants With COPD
2025-525042-22-00· Phase 1· Genentech Inc.· Source
Recruiting
Phase 1 Single Dose Study of JADE201 in Participants with Rheumatoid Arthritis
2025-524746-96-00· Phase 1· Jade Biosciences Inc.· Source
Not yet recruiting
A Participant- and Investigator--Blinded, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants with Chronic Kidney Disease
2025-520978-18-00· Phase 1· Novartis Pharma AG· Source
Recruiting
A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis
NCT07258849· Phase 1· Eli Lilly and Company· Source
Active, not recruiting
Phase 1, Randomized, Double-blind, Placebo-Controlled, First-in-Human Single Ascending Dose Study in Healthy Participants to Assess the Safety, Tolerability, and Pharmacokinetics of JNJ-95597528 and a Proof of Mechanism Study in Participants with Mild to Moderate Asthma
2024-517644-62-00· Phase 1· Janssen Cilag International· Source
Recruiting
The Sagittarius Trial
NCT06490536· Phase 3· IFOM ETS - The AIRC Institute of Molecular Oncology· Source
Recruiting
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]
NCT06264180· Phase 3· Replimune, Inc.· Source
Active, not recruiting
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
NCT06157892· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source
Recruiting
A randomized, double-blind, placebo-controlled, single and multiple-dose-escalation, phase 1 study in healthy volunteers and patients with ulcerative colitis to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GRT-001 (MONOlith trial)
2023-507547-11-00· Phase 1· Granite Bio AG· Source
Active, not recruiting
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986· Phase 1· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Investigate GB-0895 in Adults With Mild to Moderate Asthma or COPD
NCT07116889· Phase 1· Generate Biomedicines· Source
Recruiting
Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma
NCT05853965· Phase 1/2· Universitätsklinikum Hamburg-Eppendorf· Source
Recruiting
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
NCT05822908· Phase 1/2· Vico Therapeutics B. V.· Source
Active, not recruiting
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT04895696· Phase 2· Beeline Medicines Corporation· Source
Active, not recruiting
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
NCT04493853· Phase 3· AstraZeneca· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Closed trials

Recruiting
An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
NCT07665723· Phase 1· Hoffmann-La Roche· Source
Completed
GRT-1C102: A randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of GRT-001 after subcutaneous administrations to healthy subjects (MONOSqut trial).
2025-524328-24-00· Phase 1· Granite Bio AG· Source
Completed
Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations
NCT07338214· Phase 1· Zealand Pharma· Source
Completed
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
NCT06693908· Phase 1· Genentech, Inc.· Source
Completed
An Open-Label, Multicentre Phase 1b/2a Clinical Trial of BI-1607, an Fc-Engineered Monoclonal Antibody to FcγRIIB (CD32b), in Combination with Ipilimumab and Pembrolizumab in Participants with Unresectable or Metastatic Melanoma
2024-512670-10-00· Phase 1/2· BioInvent International AB· Source
Completed
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
NCT06686628· Phase 1· Sanofi· Source
Completed
A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men
NCT06649630· Phase 1· Novo Nordisk A/S· Source
Completed
A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in Participants With Reduced Kidney Function and Normal Kidney Function
NCT06559527· Phase 1· Novo Nordisk A/S· Source
Completed
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.
2023-509961-19-00· Phase 1· Novo Nordisk A/S· Source
Completed
A safety study of PF-08046045/SGN-35T in adults with advanced cancers
NCT06120504· Phase 1· Seagen Inc.· Source
Completed
A Study to Test How Well Different Doses of BI 3034701 Are Tolerated by Healthy Men and People With Overweight or Obesity
NCT06352437· Phase 1· Boehringer Ingelheim· Source
Completed
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
NCT06352424· Phase 1· Boehringer Ingelheim· Source
Completed
A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function
NCT06370819· Phase 1· Novo Nordisk A/S· Source
Completed
A study of how CagriSema works on appetite in people with excess body weight
2023-504782-23-00· Phase 1· Novo Nordisk A/S· Source
Completed
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic Dermatitis
2022-502997-18-00· Phase 1· Bristol-Myers Squibb Services Unlimited Company· Source
Completed
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the Blood
NCT05896384· Phase 1· Boehringer Ingelheim· Source
Completed
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT05571839· Phase 1· Seagen Inc.· Source
Completed
A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment
NCT06088043· Phase 3· Takeda· Source
Completed
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
NCT06013995· Phase 1· Bristol-Myers Squibb· Source
Terminated
A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain
NCT05838742· Phase 2· GlaxoSmithKline· Source
Completed
A Phase 1b, 2-part, placebo-controlled study to evaluate the efficacy, safety, and PK of PF-07054894 in participants with mild to severe UC.
NCT05549323· Phase 1· Pfizer Inc.· Source
Completed
A Study of SGN-B7H4V in Advanced Solid Tumors
NCT05194072· Phase 1· Seagen Inc.· Source
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of REGN9035 in Healthy Adult Volunteers and Mildly Hypertensive Participants
NCT05291546· Phase 1· Regeneron Pharmaceuticals· Source
Completed
A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination With Atezolizumab in Subjects with Locally Advanced and Metastatic Tumors
NCT05018273· Phase 1· Nykode Therapeutics ASA· Source
Active, not recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882· Phase 1· AbbVie· Source
Completed
Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis
NCT04886258· Phase 2· Novartis Pharmaceuticals· Source

Site data: ClinicalTrials.govUpdated 13 Nov 2026

Report an error

Under construction, not live – Charite Research Organisation GmbH: trial site – Frontlight Research